1477500-63-2

Upstream product

• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 151967-82-7 [(S)-1-[(2S,3S,4R,5R)-5-(6-Dimethylamino-purin-9-yl)-4-hydroxy-2-hydroxymethyl-tetrahydro-furan-3-ylcarbamoyl]-2-(4-methoxy-phenyl)-ethyl]-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 53-79-2 puromycin 
• 108-24-7 acetic anhydride 
• 151967-83-8 [(S)-1-[(2S,3S,4R,5R)-2-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-5-(6-dimethylamino-purin-9-yl)-4-hydroxy-tetrahydro-furan-3-ylcarbamoyl]-2-(4-methoxy-phenyl)-ethyl]-carbamic acid 9H-fluoren-9-ylmethyl ester 

Downstream Products

• 1477500-65-4 C₃₉H₄₁N₇O₈ 

Relevant academic research and scientific papers

5 the bit [...] modified purine ycin compound and its preparation and use

The invention belongs to the field of chemical invention technology, and relates to a 5'-bit modified puromycin compound, and a preparation method and applications in drug screening thereof. The structure formula of the 5'-bit modified puromycin compound is described as following: R1 is protecting group Fmoc, Boc or Cbz; and R2 is protecting group Ac, Bz or Pv. The 5'-bit modified puromycin compound can be connected to the 5'-terminal of an oligonucleotide chain by solid phase phosphoramidite triester method, and is used for polypeptide medicine screening. The preparation method is simple, synthetic efficiency is high, and the 5'-bit modified puromycin compound is suitable for commercial synthesis.

DNA display for drug discovery

A novel DNA display strategy, based on a new puromycin modifier, has been developed. The 5′-end puromycin-tethered oligonucleotide was synthesized to hybridize with mRNA, so that it could attack the nascent polypeptides during in vitro translation. The DNA-peptide fusion molecule can tolerate more harsh and stringent selection conditions, therefore, this DNA display may become a useful tool for in vitro display technologies for the selection of peptide drug candidates. The Royal Society of Chemistry 2013.